Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 2
2015 1
2021 1
2022 1
2023 6
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A, LoRusso P, Patel MR, Miller WH Jr, Garralda E, Forster MD, Santoro A, Falcon A, Kim TW, Paz-Ares L, Bowyer S, de Miguel M, Han SW, Krebs MG, Lee JS, Cheng ML, Arbour K, Massarelli E, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Dharia NV, Schutzman JL, Desai J; GO42144 Investigator and Study Group. Sacher A, et al. N Engl J Med. 2023 Aug 24;389(8):710-721. doi: 10.1056/NEJMoa2303810. N Engl J Med. 2023. PMID: 37611121 Free article. Clinical Trial.
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Desai J, et al. Among authors: cosman r. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5. Nat Med. 2024. PMID: 38052910 Free PMC article. Clinical Trial.
Fairness for all.
Precious DS, Cosman RW. Precious DS, et al. Among authors: cosman rw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Oct;116(4):385. doi: 10.1016/j.oooo.2013.06.036. Epub 2013 Aug 6. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013. PMID: 23928209 No abstract available.
LXS196 for Metastatic Uveal Melanoma - finally some progress.
Rodrigues A, Cosman R, Joshua AM. Rodrigues A, et al. Among authors: cosman r. Br J Cancer. 2023 May;128(10):1791-1793. doi: 10.1038/s41416-023-02199-w. Epub 2023 Mar 1. Br J Cancer. 2023. PMID: 36859685 Free PMC article.
Single-Agent Divarasib in Patients With KRAS G12C-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.
Sacher AG, Miller WH Jr, Patel MR, Paz-Ares L, Santoro A, Ahn MJ, Dziadziuszko R, Freres P, Luo J, Bowyer S, Desai J, Markman B, De Miguel M, Deva S, Falcon A, Alonso G, Guedes JD, Kim SH, Krebs MG, Laurie SA, Massarelli E, Medina L, Prenen H, Amatu A, Van Dongen M, Choi Y, Hou X, Qi T, Lin MT, Koli K, Mayo MC, Yau KK, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL, Lorusso P; GO42144 Investigator Study group; GO42144 Investigator Study Group. Sacher AG, et al. J Clin Oncol. 2025 Jul 9:JCO2500040. doi: 10.1200/JCO-25-00040. Online ahead of print. J Clin Oncol. 2025. PMID: 40632992
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.
Liu J, Minchom AR, Greystoke A, Evans TRJ, Sarker D, Joshua AM, Morton C, Yau W, Aktas BY, Cosman R, Cohen JE, Edmondson SR, Paull JRA, Jean-Francois BM, Main NJ, Angeles J, Castellarnau A, Cook N. Liu J, et al. Among authors: cosman r. J Clin Oncol. 2025 Sep 10;43(26):2918-2929. doi: 10.1200/JCO-25-00236. Epub 2025 Aug 1. J Clin Oncol. 2025. PMID: 40749148 Clinical Trial.
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, Carlino MS, Pachynski RK, Cosman R, Chu QS, Damian S, Curigliano G, Tam R, Wang X, Jeyamohan C, Wang L, Zhu L, Santucci-Pereira J, Greenawalt DM, Tabernero J. Luke JJ, et al. Among authors: cosman r. Clin Cancer Res. 2025 Jun 3;31(11):2134-2144. doi: 10.1158/1078-0432.CCR-24-0439. Clin Cancer Res. 2025. PMID: 39670852 Clinical Trial.
18 results